Limits...
Preferential autoimmune response in prostate cancer to cyclin B1 in a panel of tumor-associated antigens.

Dai L, Li J, Ortega R, Qian W, Casiano CA, Zhang JY - J Immunol Res (2014)

Bottom Line: Autoantibodies to cyclin B1 and fourteen other TAAs were detected by enzyme-linked immunosorbent assay (ELISA) and Western blotting in 464 sera from patients with PCa, benign prostatic hyperplasia (BPH), and other controls.In the further analysis, 31.4% of sera from PCa patients at the early stage contained anti-cyclin B1 autoantibody, and even 29.4% of patients who had normal prostate-specific antigen (PSA) levels in their serum samples were observed anti-cyclin B1 positive.This study further supports the hypothesis that a customized TAA array can be used for enhancing anti-TAA autoantibody detection, and it may constitute a promising and powerful tool for immunodiagnosis of PCa.

View Article: PubMed Central - PubMed

Affiliation: Department of Biological Sciences, The University of Texas at El Paso, El Paso, TX 79968, USA.

ABSTRACT
Previous studies have demonstrated that sera from patients with prostate cancer (PCa) contain autoantibodies that react with tumor-associated antigens (TAAs). Autoantibodies to cyclin B1 and fourteen other TAAs were detected by enzyme-linked immunosorbent assay (ELISA) and Western blotting in 464 sera from patients with PCa, benign prostatic hyperplasia (BPH), and other controls. Autoantibodies to cyclin B1 were detected in 31.0% of sera from randomly selected patients with PCa versus 4.8% in sera with BPH. In the further analysis, 31.4% of sera from PCa patients at the early stage contained anti-cyclin B1 autoantibody, and even 29.4% of patients who had normal prostate-specific antigen (PSA) levels in their serum samples were observed anti-cyclin B1 positive. The cumulative positive rate of autoantibodies against seven selected TAAs (cyclin B1, survivin, p53, DFS70/LEDGFp75, RalA, MDM2, and NPM1) in PCa reached 80.5%, significantly higher than that in normal control sera. In summary, autoantibody to cyclin B1 might be a potential biomarker for the immunodiagnosis of early stage PCa, especially useful in patients with normal PSA level. This study further supports the hypothesis that a customized TAA array can be used for enhancing anti-TAA autoantibody detection, and it may constitute a promising and powerful tool for immunodiagnosis of PCa.

Show MeSH

Related in: MedlinePlus

(a) Antibody titers to cyclin B1 in ELISA were expressed as optical density (OD) units. The mean + 3SD of normal human sera are shown in relationship to PCa and BPH. (b) Western blotting analysis shows antibody reactivity to cyclin B1 before and after absorption in nitrocellulose membrane strips blotted with purified recombinant cyclin B1 protein. Lanes 1–3 are sera from PCa patients and the corresponding OD values of these sera are indicated in panel (a). In general, OD values in ELISA were related to intensity of signals in Western blotting and the signals decreased obviously after sera absorption.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4016862&req=5

fig1: (a) Antibody titers to cyclin B1 in ELISA were expressed as optical density (OD) units. The mean + 3SD of normal human sera are shown in relationship to PCa and BPH. (b) Western blotting analysis shows antibody reactivity to cyclin B1 before and after absorption in nitrocellulose membrane strips blotted with purified recombinant cyclin B1 protein. Lanes 1–3 are sera from PCa patients and the corresponding OD values of these sera are indicated in panel (a). In general, OD values in ELISA were related to intensity of signals in Western blotting and the signals decreased obviously after sera absorption.

Mentions: As shown in Figure 1(a) and Table 1, 54 of 174 (31.0%) PCa sera had autoantibodies to cyclin B1 with OD values over cut-off higher than NHS (2.2%). Only the OD value in one BPH serum was over the cut-off line. All of sera with OD value over the cut-off in ELISA were confirmed by Western blotting using purified cyclin B1 protein as antigen. Forty-nine of 54 (90.7%) with higher OD value for cyclin B1 from PCa were also positive in Western blotting. In general, higher OD value in ELISA gave the stronger signals in Western blotting, and, after the sera were absorbed using purified cyclin B1 protein, the signals were obviously decreased and they even disappeared (Figure 1(b)). The variations between the two different immunological assays might be related to the increased sensitivity of ELISA over Western blotting, but other possibilities could be related to recognition of different epitopes on the same antigen in the two assays.


Preferential autoimmune response in prostate cancer to cyclin B1 in a panel of tumor-associated antigens.

Dai L, Li J, Ortega R, Qian W, Casiano CA, Zhang JY - J Immunol Res (2014)

(a) Antibody titers to cyclin B1 in ELISA were expressed as optical density (OD) units. The mean + 3SD of normal human sera are shown in relationship to PCa and BPH. (b) Western blotting analysis shows antibody reactivity to cyclin B1 before and after absorption in nitrocellulose membrane strips blotted with purified recombinant cyclin B1 protein. Lanes 1–3 are sera from PCa patients and the corresponding OD values of these sera are indicated in panel (a). In general, OD values in ELISA were related to intensity of signals in Western blotting and the signals decreased obviously after sera absorption.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4016862&req=5

fig1: (a) Antibody titers to cyclin B1 in ELISA were expressed as optical density (OD) units. The mean + 3SD of normal human sera are shown in relationship to PCa and BPH. (b) Western blotting analysis shows antibody reactivity to cyclin B1 before and after absorption in nitrocellulose membrane strips blotted with purified recombinant cyclin B1 protein. Lanes 1–3 are sera from PCa patients and the corresponding OD values of these sera are indicated in panel (a). In general, OD values in ELISA were related to intensity of signals in Western blotting and the signals decreased obviously after sera absorption.
Mentions: As shown in Figure 1(a) and Table 1, 54 of 174 (31.0%) PCa sera had autoantibodies to cyclin B1 with OD values over cut-off higher than NHS (2.2%). Only the OD value in one BPH serum was over the cut-off line. All of sera with OD value over the cut-off in ELISA were confirmed by Western blotting using purified cyclin B1 protein as antigen. Forty-nine of 54 (90.7%) with higher OD value for cyclin B1 from PCa were also positive in Western blotting. In general, higher OD value in ELISA gave the stronger signals in Western blotting, and, after the sera were absorbed using purified cyclin B1 protein, the signals were obviously decreased and they even disappeared (Figure 1(b)). The variations between the two different immunological assays might be related to the increased sensitivity of ELISA over Western blotting, but other possibilities could be related to recognition of different epitopes on the same antigen in the two assays.

Bottom Line: Autoantibodies to cyclin B1 and fourteen other TAAs were detected by enzyme-linked immunosorbent assay (ELISA) and Western blotting in 464 sera from patients with PCa, benign prostatic hyperplasia (BPH), and other controls.In the further analysis, 31.4% of sera from PCa patients at the early stage contained anti-cyclin B1 autoantibody, and even 29.4% of patients who had normal prostate-specific antigen (PSA) levels in their serum samples were observed anti-cyclin B1 positive.This study further supports the hypothesis that a customized TAA array can be used for enhancing anti-TAA autoantibody detection, and it may constitute a promising and powerful tool for immunodiagnosis of PCa.

View Article: PubMed Central - PubMed

Affiliation: Department of Biological Sciences, The University of Texas at El Paso, El Paso, TX 79968, USA.

ABSTRACT
Previous studies have demonstrated that sera from patients with prostate cancer (PCa) contain autoantibodies that react with tumor-associated antigens (TAAs). Autoantibodies to cyclin B1 and fourteen other TAAs were detected by enzyme-linked immunosorbent assay (ELISA) and Western blotting in 464 sera from patients with PCa, benign prostatic hyperplasia (BPH), and other controls. Autoantibodies to cyclin B1 were detected in 31.0% of sera from randomly selected patients with PCa versus 4.8% in sera with BPH. In the further analysis, 31.4% of sera from PCa patients at the early stage contained anti-cyclin B1 autoantibody, and even 29.4% of patients who had normal prostate-specific antigen (PSA) levels in their serum samples were observed anti-cyclin B1 positive. The cumulative positive rate of autoantibodies against seven selected TAAs (cyclin B1, survivin, p53, DFS70/LEDGFp75, RalA, MDM2, and NPM1) in PCa reached 80.5%, significantly higher than that in normal control sera. In summary, autoantibody to cyclin B1 might be a potential biomarker for the immunodiagnosis of early stage PCa, especially useful in patients with normal PSA level. This study further supports the hypothesis that a customized TAA array can be used for enhancing anti-TAA autoantibody detection, and it may constitute a promising and powerful tool for immunodiagnosis of PCa.

Show MeSH
Related in: MedlinePlus